-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
September 19, 2020 /--- Adrenatics are a key ingredient in many modern vaccines that trigger an immune response to help protect the body from disease.
scientists believe adrenatics are key to developing new vaccines against viruses that are difficult to eradicate, such as HIV.
but advents can cause inflammation at the injection site, as well as side effects of overstulging the immune system, which prevents many promising new candidates from being integrated into the vaccine.
a new study, researchers from the University of Chicago's Pritzker School of Molecular Engineering have discovered a new way to limit inflammation caused by adulations: by adding a molecule to disrupt certain pathways in cells.
this molecule not only reduces inflammatory susceptivity, but also appears to have an additional benefit of increasing the protective response to viruses such as influenza, dengue and even HIV.
could eventually be used to develop a vaccine against SARS-CoV-2--- which causes the coronavirus to --- COVID-19.
study was recently published in the journal Science Advances under the title "Increased vaccine tolerability and protection via NF-B Modulation".
images from Science Advances, 2020, doi:10.1126/sciadv.aaz8700.
lead to the development of a new way to design vaccines," said Aaron Esser-Kahn, a co-author of the paper and an associate professor at the University of Chicago's Pritzker School of Molecular Engineering.
goes against the conventional view that increasing inflammation is necessary and that doing so provides more protection.
it's more beneficial than we'd like.
scientists have been exploring the use of Tol-like lily (TLR) agonists as adrenasts for years because they activate inflammatory cytokines to make vaccines work.
agonist called CpG DNA has been shown to be a adrenast, and it has even been shown to prevent HIV infection.
but TLR agonists like CpG DNA can induce excessive inflammatory reactions in the body, making it difficult to use in vaccine development.
, "In the field of vaccines, you hear time and time again that you just need to accept inflammation from a single molecule," says Esser-Kahn, a research group.
, however, we wanted to find a way to limit the ability of cells to respond to inflammation-related cytokines.
we want to decoupling the initial, unwanted inflammation from the actual effective immune system response.
" Esser-Kahn and his team found that a peptide called SN50 can disrupt the path of this initial inflammation in cells.
specifically, it destroys a protein called NF-kB, which is known to play a role in the production of inflammatory cytokines.
added it to different TLR agitants, they found that it reduced inflammation and, more surprisingly, increased antibody production against disease.
, "It's very simple and doesn't require a lot of extra material," said Esser-Kahn, a spokesman for the Group.
this is an adjustment to the way cells process information.
to test the effectiveness of SN50 in mice with several different diseases in order to test the effectiveness of molecules that fight influenza viruses and HIV.
in the case of dengue virus, they found that SN50 helps produce more antibodies to the virus.
in the case of HIV, they have found that it helps produce antibodies that target hard-to-reach parts of the virus, overcoming one of the obstacles that make hiv vaccines difficult to build.
when the researchers added SN50 to an existing flu vaccine, they found it increased its level of protection against the vaccine.
SN50 molecule reduced inflammation, but we were surprised to see that it provided more protection at the same time," said Esser-Kahn, a researcher at the SN50.
" next, the researchers hope to find a small molecule that can do the same, and are studying how such molecules could also help develop immunotherapy for cancer and other diseases.
, the new study could help develop a new vaccine against SARS-CoV-2, especially if the virus mutates into a seasonal virus.
s approach has a big impact on how we design vaccines in the next five or ten years," said Esser-Kahn, an esser-Kahn research group.
(bioon.com) Reference: 1.B. A. Moser et al. Increased vaccine tolerability and protection via NF-kB Modulation, Science Advances, 2020, doi:10.1126/sciadv.aaz8700.2.New vaccine design reduces, adders protection.